Beovu is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD). Inhibition of the VEGF pathway is believed to impede the growth of neovascular lesions, resolve retinal edema, and improve vision in patients with neovascular AMD.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Scenesse (Afamelanotide) for Erythropoietic Protoporphyria
Scenesse is a subcutaneous implant containing a synthetic analog of alpha-melanocyte stimulating hormone. It is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.
Scenesse (Afamelanotide) for Erythropoietic Protoporphyria
Scenesse is a subcutaneous implant containing a synthetic analog of alpha-melanocyte stimulating hormone. It is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria.
Endari (Pharmaceutical Grade L-Glutamine)
Endari (oral pharmaceutical grade L-glutamine) is an amino acid with antioxidant properties indicated to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. It is a precursor for nicotinamide adenine dinucleotide (NAD), which is deficient in patients with SCD. A definitive mechanism of action is not yet defined…
Endari (Pharmaceutical Grade L-Glutamine)
Endari (oral pharmaceutical grade L-glutamine) is an amino acid with antioxidant properties indicated to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older. It is a precursor for nicotinamide adenine dinucleotide (NAD), which is deficient in patients with SCD. A definitive mechanism of action is not yet defined…
Ofev (Nintedanib) for Systemic Sclerosis-Associated Interstitial Lung Disease
Ofev (nintedanib) is a small molecule that inhibits multiple receptor tyrosine kinases that play an important role in the pathogenesis of fibrosis. The inhibition of these receptors is believed to decrease collagen and fibronectin formation, thereby slowing the rate of decline in pulmonary function in patients with systemic sclerosis.
Ofev (Nintedanib) for Systemic Sclerosis-Associated Interstitial Lung Disease
Ofev (nintedanib) is a small molecule that inhibits multiple receptor tyrosine kinases that play an important role in the pathogenesis of fibrosis. The inhibition of these receptors is believed to decrease collagen and fibronectin formation, thereby slowing the rate of decline in pulmonary function in patients with systemic sclerosis.
Xpovio (Selinexor) for Relapsed/Refractory Multiple Myeloma
Xpovio is a first-in-class oral selective inhibitor of the nuclear export protein exportin-1 (XPO1). Xpovio is believed to bind with and inhibit XPO1, causing tumor suppressor proteins to accumulate in the cell nucleus and inducing apoptosis in cancer cells while preserving normal cells. It is indicated to treat patients with heavily pretreated relapsed/refractory multiple my…
Xpovio (Selinexor) for Relapsed/Refractory Multiple Myeloma
Xpovio is a first-in-class oral selective inhibitor of the nuclear export protein exportin-1 (XPO1). Xpovio is believed to bind with and inhibit XPO1, causing tumor suppressor proteins to accumulate in the cell nucleus and inducing apoptosis in cancer cells while preserving normal cells. It is indicated to treat patients with heavily pretreated relapsed/refractory multiple my…
Barostim Neo System for Heart Failure
The Barostim neo System is an implantable neuromodulation device designed to improve cardiac function by delivering electrical stimulation to baroreceptors in the wall of the carotid artery. The system is designed to take advantage of the body’s natural baroreflex system. Activation of baroreceptors in the wall of the carotid artery with baroreflex activation therapy stimulat…